On Mar. 26, 2013, GlaxoSmithKline and the Texas A&M University System announced that the U.S. Department of Health and Human Services approved the establishment of a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing in Bryan-College Station, Texas.